Medical News

RSS

CPEX third quarter revenues increase 17% to $5.8 million

CPEX Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2010. For the quarter CPEX reported revenues of $5.8 million and net income of $2.4 million.

8 Nov 2010

FDA authorizes Athersys' MultiStem Phase II clinical trial for ulcerative colitis

Athersys, Inc. announced today that the U.S. Food and Drug Administration (FDA) has authorized commencement of a Phase II clinical trial evaluating the safety and efficacy of administration of MultiStem, Athersys' allogeneic investigational cell therapy product, for the potential treatment of ulcerative colitis.

8 Nov 2010

Alliance Data to provide private label credit services to American Laser Centers

Alliance Data Systems Corporation, a leading provider of loyalty and marketing solutions derived from transaction-rich data, today announced it has signed a long-term agreement with American Laser Centers to provide private label credit services designed to drive sales and enhance long-term customer loyalty.

8 Nov 2010

Parascript receives $244,479.25 federal grant under Affordable Care Act

Parascript, LLC, the image analysis and pattern recognition technology provider, today announced that it was awarded a cash grant of $244,479.25 under the U.S. Government's Affordable Care Act. Under this act, the therapeutic discovery project program targets projects that show significant potential to produce new therapies, address unmet medical needs, reduce the long-term growth of health care costs or advance the goal of curing cancer within the next 30 years.

8 Nov 2010

Potential new biomarkers for very early prostate cancer

A new study presented at the National Cancer Research Institute (NCRI) conference in Liverpool next week has found potential new biomarkers for very early prostate cancer in men with no symptoms of the disease.

8 Nov 2010

Hyperuricemia associated with increased risk for hypertension

People with hyperuricemia are at an increased risk for high blood pressure, according to research presented at the Nov 2010, American College of Rheumatology Annual Scientific Meeting in Atlanta.

8 Nov 2010

MAP Pharmaceuticals reports positive results from LEVADEX QT trial for migraine

MAP Pharmaceuticals, Inc. today reported successful results from a thorough QT trial of its investigational LEVADEX™ orally inhaled migraine therapy. The trial evaluated the potential of a supra-therapeutic dose to cause an increase in the QT interval. Results of the trial showed that a supra-therapeutic dose of LEVADEX does not increase QTc intervals. LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 efficacy development for the acute treatment of migraine.

8 Nov 2010

Chronic fatigue syndrome associated with maladaptive personality features and personality disorders

This study suggests that chronic fatigue syndrome is associated with an increased prevalence of maladaptive personality features and personality disorders. This might be associated with being noncompliant with treatment suggestions, displaying unhealthy behavioral strategies and lacking a stable social environment.

8 Nov 2010

Manhattan awarded $244,279 grant under QTDP program

Manhattan Pharmaceuticals, Inc. announced today that it has been awarded $244,279 in funding under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) credit program. The Company has received this funding for its lead product candidate AST-726 for the treatment of vitamin B12 deficiency.

8 Nov 2010

MedCath to sell Texsan Heart Hospital

MedCath Corporation announced today it has entered into a definitive agreement to sell substantially all the assets of Texsan Heart Hospital, owned by MedCath and its physician investors, to Methodist Healthcare System of San Antonio. The transaction is expected to close during MedCath's second fiscal quarter of 2011, which ends March 31, subject to regulatory approval and customary closing conditions.

8 Nov 2010

Guided Therapeutics receives $244,479 federal grant to advance LightTouch Cervical Scanner

Guided Therapeutics, Inc. announced that it received a $244,479 Federal grant to advance its LightTouch™ Cervical Scanner, currently under FDA review for market approval.

8 Nov 2010

GRS and CORRONA enter strategic partnership for clinical research in rheumatoid arthritis

Global Research Services, LLC (GRS), an international full-service clinical research organization (CRO), and The Consortium of Rheumatology Researchers of North America, Inc. (CORRONA), the largest independent initiative for clinical research in rheumatoid arthritis, announced today their strategic partnership to bring together Phase I-IV clinical research capabilities with the largest rheumatology patient registry in North America.

8 Nov 2010

Gentium third quarter total revenues increase to EUR 5.91 million

Gentium S.p.A. today reported financial results for the quarter ended September 30, 2010. The Company reports its financial condition and operating results using U.S. Generally Accepted Accounting Principles (GAAP). The Company's financial statements are prepared using the Euro as its functional currency.

8 Nov 2010

First Edition: November 8, 2010

Today's health policy headlines include more post-mortem reports about the health law's impact on the election.

8 Nov 2010

Spaceflights negatively impact bone health

Long-duration spaceflight may have a long-term negative impact on bone health, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

8 Nov 2010

Structural deformities affect typing styles of touch typists with rheumatoid arthritis

Joint damage caused by rheumatoid arthritis can lead to difficulties in typing and can force people to seek alternative—but potentially more destructive—ways of putting their fingers to the keyboard, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

8 Nov 2010

Solutia sells Perkalink business

Solutia Inc. announced today that it has sold its Perkalink® business and entered into a definitive agreement to sell select Primary Accelerators assets to LANXESS, a Germany-based specialty chemicals company.

8 Nov 2010

Gents renews distribution agreement for AcnEase with Herborium

Herborium Group, Inc., a Botanical Therapeutics™ company, during its shareholder conference call yesterday afternoon, announced that Gents, AB of Helsingborg, Sweden, renewed its distribution agreement to supply AcnEase® throughout Sweden.

8 Nov 2010

Apples lower risk for developing heart disease

Recent research out of the University of Michigan Health System – a premier academic medical center – has found that adding more apples and apple products to your diet may be an easy way to lower your risk for developing heart disease. More than one in three U.S. adults has one or more types of cardiovascular disease (CVD) according to the American Heart Association. Heart disease is the leading cause of death in the United States.

8 Nov 2010

Community Health Systems amends existing credit agreement with subsidiary

Community Health Systems, Inc. today announced that on November 5, 2010, it and its wholly-owned subsidiary CHS/Community Health Systems, Inc. entered into an amendment and restatement (the "Amendment") of their existing credit agreement, dated as of July 25, 2007 (as amended and restated, the "Credit Agreement").

8 Nov 2010